Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | NQO2 | P16083 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753222 | 0.81 | ENPP3 (0.45) | MAPTENPP3ENPP1GAAALDH1A1 | |
| SCHEMBL6025148 | 0.81 | MAPT (0.44) | MAPTENPP3ENPP1GAAALDH1A1 | |
| SCHEMBL17867403 | 0.79 | CYP1A2 (0.47) | MAPTGAAALDH1A1KMT2AKDM4E | |
| SCHEMBL14391599 | 0.76 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL5756488 | 0.76 | ELANE (0.44) | MAPTGAAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL15845928 | 0.76 | NR4A2 (0.43) | MAPTHSP90AA1KDM4ECYP1A2 | |
| SCHEMBL24711958 | 0.73 | NQO2 (0.31) | NQO2 | |
| SCHEMBL27053770 | 0.73 | NQO2 (0.31) | NQO2 | |
| SCHEMBL2158991 | 0.72 | KDM4E (0.42) | MAPTENPP3ENPP1GAAALDH1A1 | |
| SCHEMBL18688164 | 0.72 | HPRT1 (0.44) | MAPTALDH1A1USP2TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185832-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-16 | — | — | US | disclosed |
| CN-114206841-A | CD73 inhibitor | 博奥阿迪斯生物科技公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2020210938-A1 | QUINAZOLINE DERIVATIVES AS CD73 INHIBITORS | BIOARDIS LLC (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020211668-A1 | CD73 INHIBITORS | BIOARDIS LLC (US) | 2020-10-22 | — | — | WO | disclosed |
| EP-3354653-B1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD (CN) | 2019-09-04 | — | — | EP | disclosed |
| EP-3354653-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | Guangzhou Maxinovel Pharmaceuticals Co. Ltd. (CN) | 2018-08-01 | — | — | EP | disclosed |
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| EP-3287463-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
| US-20180006242-A1 | COMPOUND FOR ORGANIC OPTOELECTRONIC DIODE, ORGANIC OPTOELECTRONIC DIODE COMPRISING SAME, AND DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2018-01-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2024342-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | Pfizer Products Incorporated (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1218358-B1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1218358-A1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| US-6399603-B1 | QUINAZOLINES; RETARDING APOPTOSIS IN CELLS; INHIBITING CLEAVAGE OF PROTEIN SUBSTRATES BY CASPASE-3; CHEMICAL AND HYDROLYTIC STABILITY | ASTRAZENECA AB (SE) | 2002-06-04 | — | — | US | disclosed |
| WO-2001021598-A1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | MAPT 1800/4885ENPP3 4402/4885ENPP1 4123/4885 |
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | FLT3, FGFR1, FGFR3 | MAPT 283/4885ENPP3 2694/4885ENPP1 1868/4885 |
| US-20180006242-A1 | COMPOUND FOR ORGANIC OPTOELECTRONIC DIODE, ORGANIC OPTOELECTRONIC DIODE COMPRISING SAME, AND DISPLAY DEVICE | OR10J3, ODC1, OR51E2 | MAPT 1231/4885ENPP3 3177/4885ENPP1 2207/4885 |
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | PDK1, WEE1, DCK | MAPT 4606/4885ENPP3 4161/4885ENPP1 3252/4885 |
| US-20220185832-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | MAPT 2745/4885ENPP3 11/4885ENPP1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.